- Home
- IR vs ZTS Comparison
IR vs ZTS Comparison
Compare IR & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IR | ZTS |
|---|---|---|
| Founded | 1859 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 31.9B |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | IR | ZTS |
|---|---|---|
| Price | $84.40 | $75.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $96.00 | ★ $154.18 |
| AVG Volume (30 Days) | 3.7M | ★ 4.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | 0.10% | ★ 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | 0.49 | ★ 1.42 |
| Revenue | $2,375,400,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $7.10 | $5.63 |
| Revenue Next Year | $4.78 | $4.77 |
| P/E Ratio | $172.06 | ★ $52.51 |
| Revenue Growth | ★ 22.48 | 2.28 |
| 52 Week Low | $68.07 | $71.47 |
| 52 Week High | $100.96 | $160.48 |
Technical Indicators
Market Signals| Indicator | IR | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 46.85 |
| Support Level | $78.70 | $73.39 |
| Resistance Level | $89.98 | $78.02 |
| Average True Range (ATR) | 2.53 | 1.95 |
| MACD | 0.30 | 0.40 |
| Stochastic Oscillator | 83.85 | 51.39 |
Price Performance
Historical ComparisonAbout IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.